专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060240168A1 Chitosan foodstuff 审中-公开
标题翻译：壳聚糖食品
公开(公告)号：US20060240168A1
公开(公告)日：2006-10-26
申请号：US10544521
申请日：2004-02-06
申请人： Jo Klaveness , Einar Mustaparta , Bjarne Brudeli , Olav Smidsrod , Kjell Varum
发明人： Jo Klaveness , Einar Mustaparta , Bjarne Brudeli , Olav Smidsrod , Kjell Varum
IPC分类号： A23L1/212
CPC分类号： C08B37/003 , A23L5/273 , A23L17/40 , A23L19/19 , A23L29/275 , A23L33/22 , A61K31/722 , A61K47/36
摘要： The invention provides a foodstuff comprising a nutritional food substance and a chitosan having an FA value of at least 0.25.
摘要翻译：本发明提供一种食品，其包含营养食品物质和至少0.25的F A A值的壳聚糖。

2. 发明申请

US20060293216A1 Pharmaceutical compositions comprising an active agent and chitosan for sustained drug release or mucoadhesion 审中-公开
标题翻译：药物组合物包含活性剂和壳聚糖用于持续的药物释放或粘膜粘附
公开(公告)号：US20060293216A1
公开(公告)日：2006-12-28
申请号：US10544313
申请日：2004-02-06
申请人： Jo Klaveness , Etnar Mustaparta , Bjarne Brudeli , Olaw Smidsrod , Kjell Varum
发明人： Jo Klaveness , Etnar Mustaparta , Bjarne Brudeli , Olaw Smidsrod , Kjell Varum
IPC分类号： A61K38/17 , A61K31/722 , A61K31/60 , A61K31/192
CPC分类号： A61K31/37 , A61K9/0043 , A61K9/146 , A61K9/19 , A61K9/4866 , A61K9/5036 , A61K31/167 , A61K31/19 , A61K31/22 , A61K31/43 , A61K31/47 , A61K31/60
摘要： The invention provides a pharmaceutical composition comprising a physiologically active agent and a release sustaining or mucoadhesive agent, characterized in that said release sustaining or mucoadhesive agent comprises a chitosan having a FA of from 0.25 to 0.80.
摘要翻译：本发明提供一种包含生理活性剂和释放维持或粘膜粘附剂的药物组合物，其特征在于所述释放维持或粘膜粘附剂包含具有0.25至0.80的FATAA的壳聚糖。

3. 发明申请

US20100291206A1 ORAL DOSAGE FORM 审中-公开
标题翻译：口服剂型
公开(公告)号：US20100291206A1
公开(公告)日：2010-11-18
申请号：US12602317
申请日：2008-06-02
申请人： Jo Klaveness , Bjarne Brudeli , Pal Rongved
发明人： Jo Klaveness , Bjarne Brudeli , Pal Rongved
IPC分类号： A61K33/10 , A61K31/202 , A61K31/351 , A61K31/40 , A61K31/7008 , A61K31/519 , A61K9/20 , A61P9/00 , A61P19/00
CPC分类号： C08L5/16 , A61K9/205 , A61K9/2054 , A61K31/232 , A61K31/351 , A61K31/40 , A61K31/519 , A61K31/7008 , A61K45/06 , A61K47/6951 , A61P9/00 , A61P19/00 , B82Y5/00 , C08B37/0015 , C08L1/02 , A61K2300/00 , C08L2666/26
摘要： A pharmaceutical or nutraceutical tablet for oral administration comprising at least two fatty acids or derivatives thereof and cyclodextrin. Surprisingly, we have now found that fatty acids or derivatives thereof, especially fatty acid esters, preferably in the form of complexes with cyclodextrins prepared as stable solid materials, can easily be transformed into tablets with very high concentration of the fatty acid compound. The present inventors have realised that ideal dosage forms for these compounds are tablets and these are readily swallowed and are cheap to manufacture. In particular, the inventors have found that tablets containing complexes of fatty acids or derivatives thereof with cyclodextrin can be prepared by direct compression and moreover they can be prepared having a very high concentration of the desired active agent.
摘要翻译：一种用于口服给药的药物或营养片剂，其包含至少两种脂肪酸或其衍生物和环糊精。令人惊奇的是，现在我们已经发现脂肪酸或其衍生物，特别是脂肪酸酯，优选与作为稳定固体物质制备的环糊精的复合物形式，可以容易地转化成具有非常高浓度脂肪酸化合物的片剂。本发明人已经认识到，这些化合物的理想剂型为片剂，容易吞咽，制造便宜。特别地，本发明人已经发现，含有脂肪酸或其衍生物与环糊精的复合物的片剂可以通过直接压片制备，而且它们可以制备成具有非常高浓度的所需活性剂。

4. 发明申请

US20070259889A1 Protein Binding Compounds 审中-公开
标题翻译：蛋白结合化合物
公开(公告)号：US20070259889A1
公开(公告)日：2007-11-08
申请号：US10571890
申请日：2004-09-15
申请人： Jo Klaveness , Bjarne Brudeli
发明人： Jo Klaveness , Bjarne Brudeli
IPC分类号： A61K31/00 , A61K31/4164 , A61K31/513 , A61K31/52 , A61K31/7068 , A61K31/708 , A61K38/38 , A61K47/48 , A61P29/00 , A61P31/00 , A61P35/00
CPC分类号： A61K31/52 , A61K31/4164 , A61K31/513 , A61K31/7068 , A61K31/708 , A61K47/542 , A61K47/543
摘要： The present invention provides a prodrug compound comprising a therapeutically effective moiety coupled via a metabolically cleavable bond to a blood protein binding moiety.
摘要翻译：本发明提供了包含通过代谢可切割键与血液蛋白结合部分偶联的治疗有效部分的前药化合物。

5. 发明申请

US20110275594A1 Oral dosage form 审中-公开
标题翻译：口服剂型
公开(公告)号：US20110275594A1
公开(公告)日：2011-11-10
申请号：US13137048
申请日：2011-07-18
申请人： Jo Klaveness , Bjarne Brudeli , Pal Rongved
发明人： Jo Klaveness , Bjarne Brudeli , Pal Rongved
IPC分类号： A61K31/715 , A61P9/10
CPC分类号： C08L5/16 , A61K9/205 , A61K9/2054 , A61K31/232 , A61K31/351 , A61K31/40 , A61K31/519 , A61K31/7008 , A61K45/06 , A61K47/6951 , A61P9/00 , A61P19/00 , B82Y5/00 , C08B37/0015 , C08L1/02 , A61K2300/00 , C08L2666/26
摘要： A pharmaceutical or nutraceutical tablet for oral administration comprising at least two fatty acids or derivatives thereof and cyclodextrin.
摘要翻译：一种用于口服给药的药物或营养片剂，其包含至少两种脂肪酸或其衍生物和环糊精。

6. 发明申请

US20060270750A1 Bone cement compositions 审中-公开
标题翻译：骨水泥组合物
公开(公告)号：US20060270750A1
公开(公告)日：2006-11-30
申请号：US10552069
申请日：2004-04-05
申请人： Torsten Almen , Jo Klaveness , Bjarne Brudeli
发明人： Torsten Almen , Jo Klaveness , Bjarne Brudeli
IPC分类号： A61L24/00
CPC分类号： A61L27/50 , A61L24/001 , A61L24/06 , A61L2430/02
摘要： The present invention provides a bone cement comprising in admixture a monomer-containing liquid portion and a particulate polymer portion, wherein at least one of the portions comprises a dissolved nonpolymerizable organoiodine compound.
摘要翻译：本发明提供一种骨水泥，其包含混合含单体的液体部分和颗粒聚合物部分，其中至少一个部分包含溶解的不可聚合的有机碘化合物。

7. 发明申请

US20110052503A1 BIODEGRADABLE CONTRAST AGENTS 审中-公开
标题翻译：生物可比较对比剂
公开(公告)号：US20110052503A1
公开(公告)日：2011-03-03
申请号：US12808318
申请日：2008-12-22
申请人： Torsten Almen , Bjarne Brudeli , Fred Kjellson , Jo Klaveness , Jian-Sheng Wang
发明人： Torsten Almen , Bjarne Brudeli , Fred Kjellson , Jo Klaveness , Jian-Sheng Wang
IPC分类号： A61K49/04 , G21F1/10
CPC分类号： A61K49/0438 , A61K31/03 , A61K31/75 , A61K31/765 , A61K31/785 , A61K45/06 , A61K49/0461 , A61L29/18 , A61K2300/00
摘要： The present invention provides a radio-opaque composition comprising a cleavable, preferably enzymatically-cleavable, derivative of a physiologically tolerable organoiodine compound and a non-acrylic polymer wherein said derivative is incorporated in said non-acrylic polymer.
摘要翻译：本发明提供一种不透射线组合物，其包含生理上可耐受的有机碘化合物和非丙烯酸类聚合物的可裂解，优选可酶切割的衍生物，其中所述衍生物掺入所述非丙烯酸类聚合物中。

8. 发明申请

US20070254874A1 Modulators of Preripheral 5-Ht Receptors 有权
标题翻译： Preripheral 5-Ht受体的调节剂
公开(公告)号：US20070254874A1
公开(公告)日：2007-11-01
申请号：US10583829
申请日：2004-12-23
申请人： Jo Klaveness , Finn Levy , Bjarne Brudeli
发明人： Jo Klaveness , Finn Levy , Bjarne Brudeli
IPC分类号： A61K31/445 , A61K31/535 , A61P1/00 , C07D211/06 , C07D265/04 , C07D401/00
CPC分类号： C07D401/12 , A61K31/343 , A61K31/404 , A61K31/415 , A61K31/4184 , A61K31/428 , A61K31/445 , C07D209/14 , C07D211/22 , C07D211/26 , C07D211/58 , C07D405/12
摘要： Novel modulators of 5-HT4 receptors have been developed which have a selectivity for peripheral receptors rather than those of the central nervous systems. Theses include novel derivatives of known modulators as well as entirely novel entities. Surprisingly, the derivatised compounds of the known modulators maintain a high binding affinity to 5-HT4 receptors, despite the presence of an acidic moiety at the end of an optional chain. The entirely novel entities also exhibit good binding affinity to 5-HT4 receptors. All of the compounds of the invention have a common motif which includes a basic nitrogen moiety and an acidic moiety. The compounds of the invention, due at least in part to their high ionisation potential at physiological pH, have the unique properties of selectively for peripheral 5HT4 receptors over those of the CNS, good binding affinity, and selectively of 5HT4 receptors over other serotonin receptors.
摘要翻译：已经开发了具有对外周受体而不是中枢神经系统的选择性的5-HT 4受体的新型调节剂。论文包括已知调制剂的新型衍生物以及完全新颖的实体。令人惊奇的是，尽管已知调节剂的衍生化合物在任选链的末端存在酸性部分，但仍保持与5-HT 4受体的高结合亲和力。完全新颖的实体也表现出对5-HT4受体的良好的结合亲和力。本发明的所有化合物都具有共同的基序，其包括碱性氮部分和酸性部分。本发明的化合物至少部分地由于其在生理pH下的高电离电位具有对于周围5HT4受体的选择性优于CNS的那些的独特性质，良好的结合亲和力以及5HT4受体的选择性超过其他5-羟色胺受体。

9. 发明授权

US07834010B2 Modulators of peripheral 5-HT receptors 有权
标题翻译：周边5-HT受体的调节剂
公开(公告)号：US07834010B2
公开(公告)日：2010-11-16
申请号：US10583829
申请日：2004-12-23
申请人： Jo Klaveness , Finn Olav Levy , Bjarne Brudeli
发明人： Jo Klaveness , Finn Olav Levy , Bjarne Brudeli
IPC分类号： A61K31/536 , C07D265/12
CPC分类号： C07D401/12 , A61K31/343 , A61K31/404 , A61K31/415 , A61K31/4184 , A61K31/428 , A61K31/445 , C07D209/14 , C07D211/22 , C07D211/26 , C07D211/58 , C07D405/12
摘要： The invention relates to modulators of peripheral 5-HT receptors, particularly 5-HT4 receptors, said modulators essentially selective for peripheral 5-HT receptors over receptors of the central nervous system. The invention allows for the treatment, amongst others, of gastrointestinal disorders, lower urinary tract disorders, and cardiovascular disorders without side effects related to CNS activity.
摘要翻译：本发明涉及外周5-HT受体，特别是5-HT 4受体的调节剂，所述调节剂基本上对中枢神经系统受体的外周5-HT受体具有选择性。本发明允许治疗胃肠疾病，下尿路疾病和心血管疾病，而不伴随CNS活性的副作用。

10. 发明申请

US20100137266A1 TREATMENT OF INSULIN RESISTANCE AND DISORDERS ASSOCIATED THEREWITH 审中-公开
标题翻译：治疗与其相关的胰岛素抵抗和疾病
公开(公告)号：US20100137266A1
公开(公告)日：2010-06-03
申请号：US12444574
申请日：2007-10-08
申请人： Eili Tranheim Kase , Arild Chr. Rustan , Gunn Hege Thoresen , Hilde Irene Nebb , Pål Rongved , Jo Klaveness , Bjarne Brudeli
发明人： Eili Tranheim Kase , Arild Chr. Rustan , Gunn Hege Thoresen , Hilde Irene Nebb , Pål Rongved , Jo Klaveness , Bjarne Brudeli
IPC分类号： A61K31/575 , A61P3/10 , A61P3/04
CPC分类号： A61K31/575 , A61K45/06 , C07J9/00 , A61K2300/00
摘要： The present invention provides the use of an LXR antagonist, or a physiologically-acceptable pro-drug therefor, in the manufacture of a medicament for combating insulin resistance or a disorder associated therewith. Further provided is a compound being an ester or carbamate of a hydroxycholesterol, a pharmaceutical composition of such a compound or its use in therapy.
摘要翻译：本发明提供LXR拮抗剂或其生理上可接受的前药用于制备用于对抗胰岛素抵抗或与其相关的病症的药物的用途。还提供了一种化合物，其是羟基胆固醇的酯或氨基甲酸酯，这种化合物的药物组合物或其在治疗中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式